Cargando…

Mucosal Immunity After Novel COVID-19 Infection – Virus-Induced Immunosuppression: Preliminary Study

In recovered COVID-19 patients, the state of mucosal immunity remains understudied. Cytological, functional, and metabolic characteristics of neutrophils and the interleukin status will help to correctly assess the need for immunorehabilitation measures. The study objective is to assess the state of...

Descripción completa

Detalles Bibliográficos
Autores principales: Agafonova, Elena, Reshetnikova, Irina, Rizvanova, Farida
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437408/
https://www.ncbi.nlm.nih.gov/pubmed/36068809
http://dx.doi.org/10.1007/s12668-022-01020-x
_version_ 1784781602979577856
author Agafonova, Elena
Reshetnikova, Irina
Rizvanova, Farida
author_facet Agafonova, Elena
Reshetnikova, Irina
Rizvanova, Farida
author_sort Agafonova, Elena
collection PubMed
description In recovered COVID-19 patients, the state of mucosal immunity remains understudied. Cytological, functional, and metabolic characteristics of neutrophils and the interleukin status will help to correctly assess the need for immunorehabilitation measures. The study objective is to assess the state of mucosal immunity after COVID-19. A comprehensive study of mucosal immunity included the assessment of nasal mucosal neutrophils with the monitoring of destructive and apoptotic changes as well as examination of the functional and metabolic activity of neutrophils entering the nasal secretions. Phagocytic activity was assessed using microbial suspension of Staphylococcus aureus, as well as intracellular oxygen-dependent biocidity, the functions of capturing, absorbing, and killing pathogens. Study of the secretory component included assessment of interleukin levels (TNF-α, IL-10, IFN-γ) and the content of sCD95 (sAPO-1/FAS), membrane marker of apoptosis, in the nasal secretions. Cell wall neutrophils in recovered COVID-19 patients show enhanced destructive and apoptotic processes within the cells. Functional disorders due to inhibited phagocytosis of autoflora are recorded. Functionally defective cells are brought into the nasal secretions; they demonstrate severely inhibited oxygen-dependent biocidity, rapid depletion of reserves, incomplete phagocytosis, and limited ability to capture pathogens, which can contribute to the growth of various pathogenic viruses and bacteria. In the nasal secretions, the concentration of sCD95 (sAPO-1/FAS), the membrane marker of apoptosis, is increased. Elevated level of pro- and anti-inflammatory cytokines (TNF-α, IL-10) downregulates IFN-γ, thus directly contributing to the formation of functionally defective neutrophils. Compensatory increase in the IL-10 anti-inflammatory cytokine under the influence of SARS-CoV-2 virus proteins downregulates IFN-γ and is a cofactor of depression of intracellular biocidity of neutrophils. An increased level of the TNF-α pro-inflammatory cytokine increases apoptotic and destructive changes in neutrophils entering the nasal secretion. Virus-induced, functional, and metabolic impairment of neutrophils of the mucosal immunity system develop in recovered COVID-19 patients, thus providing a scientific rationale for immunomodulatory therapy.
format Online
Article
Text
id pubmed-9437408
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-94374082022-09-02 Mucosal Immunity After Novel COVID-19 Infection – Virus-Induced Immunosuppression: Preliminary Study Agafonova, Elena Reshetnikova, Irina Rizvanova, Farida Bionanoscience Article In recovered COVID-19 patients, the state of mucosal immunity remains understudied. Cytological, functional, and metabolic characteristics of neutrophils and the interleukin status will help to correctly assess the need for immunorehabilitation measures. The study objective is to assess the state of mucosal immunity after COVID-19. A comprehensive study of mucosal immunity included the assessment of nasal mucosal neutrophils with the monitoring of destructive and apoptotic changes as well as examination of the functional and metabolic activity of neutrophils entering the nasal secretions. Phagocytic activity was assessed using microbial suspension of Staphylococcus aureus, as well as intracellular oxygen-dependent biocidity, the functions of capturing, absorbing, and killing pathogens. Study of the secretory component included assessment of interleukin levels (TNF-α, IL-10, IFN-γ) and the content of sCD95 (sAPO-1/FAS), membrane marker of apoptosis, in the nasal secretions. Cell wall neutrophils in recovered COVID-19 patients show enhanced destructive and apoptotic processes within the cells. Functional disorders due to inhibited phagocytosis of autoflora are recorded. Functionally defective cells are brought into the nasal secretions; they demonstrate severely inhibited oxygen-dependent biocidity, rapid depletion of reserves, incomplete phagocytosis, and limited ability to capture pathogens, which can contribute to the growth of various pathogenic viruses and bacteria. In the nasal secretions, the concentration of sCD95 (sAPO-1/FAS), the membrane marker of apoptosis, is increased. Elevated level of pro- and anti-inflammatory cytokines (TNF-α, IL-10) downregulates IFN-γ, thus directly contributing to the formation of functionally defective neutrophils. Compensatory increase in the IL-10 anti-inflammatory cytokine under the influence of SARS-CoV-2 virus proteins downregulates IFN-γ and is a cofactor of depression of intracellular biocidity of neutrophils. An increased level of the TNF-α pro-inflammatory cytokine increases apoptotic and destructive changes in neutrophils entering the nasal secretion. Virus-induced, functional, and metabolic impairment of neutrophils of the mucosal immunity system develop in recovered COVID-19 patients, thus providing a scientific rationale for immunomodulatory therapy. Springer US 2022-09-02 2022 /pmc/articles/PMC9437408/ /pubmed/36068809 http://dx.doi.org/10.1007/s12668-022-01020-x Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Agafonova, Elena
Reshetnikova, Irina
Rizvanova, Farida
Mucosal Immunity After Novel COVID-19 Infection – Virus-Induced Immunosuppression: Preliminary Study
title Mucosal Immunity After Novel COVID-19 Infection – Virus-Induced Immunosuppression: Preliminary Study
title_full Mucosal Immunity After Novel COVID-19 Infection – Virus-Induced Immunosuppression: Preliminary Study
title_fullStr Mucosal Immunity After Novel COVID-19 Infection – Virus-Induced Immunosuppression: Preliminary Study
title_full_unstemmed Mucosal Immunity After Novel COVID-19 Infection – Virus-Induced Immunosuppression: Preliminary Study
title_short Mucosal Immunity After Novel COVID-19 Infection – Virus-Induced Immunosuppression: Preliminary Study
title_sort mucosal immunity after novel covid-19 infection – virus-induced immunosuppression: preliminary study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437408/
https://www.ncbi.nlm.nih.gov/pubmed/36068809
http://dx.doi.org/10.1007/s12668-022-01020-x
work_keys_str_mv AT agafonovaelena mucosalimmunityafternovelcovid19infectionvirusinducedimmunosuppressionpreliminarystudy
AT reshetnikovairina mucosalimmunityafternovelcovid19infectionvirusinducedimmunosuppressionpreliminarystudy
AT rizvanovafarida mucosalimmunityafternovelcovid19infectionvirusinducedimmunosuppressionpreliminarystudy